These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 17573955)

  • 1. The Pro variant of the p53 codon 72 polymorphism is associated with hepatocellular carcinoma in Moroccan population.
    Ezzikouri S; El Feydi AE; Chafik A; Benazzouz M; El Kihal L; Afifi R; Hassar M; Pineau P; Benjelloun S
    Hepatol Res; 2007 Sep; 37(9):748-54. PubMed ID: 17573955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between the p53 codon 72 Arg/Pro polymorphism and hepatocellular carcinoma risk.
    Lv L; Wang P; Zhou X; Sun B
    Tumour Biol; 2013 Jun; 34(3):1451-9. PubMed ID: 23564481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [p53 gene codon 72 polymorphism and genetic susceptibility to hepatocellular carcinoma in Chinese population].
    Zhu ZZ; Cong WM; Liu SF; Dong H; Zhu GS; Wu MC
    Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(2):76-9. PubMed ID: 15774209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association between polymorphism of P53 codon 72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3704 cases.
    Hu S; Zhao L; Yang J; Hu M
    Meta Gene; 2013 Dec; 1():126-37. PubMed ID: 25606382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 codon 72 polymorphism and hepatocellular carcinoma: a meta-analysis.
    Jia S; Tang W; Luo Y
    Hepatol Int; 2013 Jun; 7(2):669-75. PubMed ID: 26201800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population.
    Zhu ZZ; Cong WM; Liu SF; Dong H; Zhu GS; Wu MC
    World J Gastroenterol; 2005 Jan; 11(2):289-92. PubMed ID: 15633234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of p53 codon 72 polymorphism with susceptibility to hepatocellular carcinoma in a Chinese population from northeast Sichuan.
    Cai J; Cai Y; Ma Q; Chang F; Xu L; Zhang G; Guo X
    Biomed Rep; 2017 Feb; 6(2):217-222. PubMed ID: 28357076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers.
    Yu MW; Yang SY; Chiu YH; Chiang YC; Liaw YF; Chen CJ
    Hepatology; 1999 Mar; 29(3):697-702. PubMed ID: 10051470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A p53 polymorphism modifies the risk of hepatocellular carcinoma among non-carriers but not carriers of chronic hepatitis B virus infection.
    Zhu ZZ; Cong WM; Liu SF; Xian ZH; Wu WQ; Wu MC; Gao B; Hou LF; Zhu GS
    Cancer Lett; 2005 Nov; 229(1):77-83. PubMed ID: 15979781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma.
    Anzola M; Cuevas N; López-Martínez M; Saiz A; Burgos JJ; de Pancorbo MM
    Cancer Lett; 2003 Apr; 193(2):199-205. PubMed ID: 12706878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of p53 codon 72 polymorphism with risk of hypopharyngeal squamous cell carcinoma in Taiwan.
    Twu CW; Jiang RS; Shu CH; Lin JC
    J Formos Med Assoc; 2006 Feb; 105(2):99-104. PubMed ID: 16477330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.
    Qiu M; Liu Y; Yu X; Qin L; Bei C; Zeng X; Qiu X; Tang B; He S; Yu H
    Tumour Biol; 2016 Mar; 37(3):3863-70. PubMed ID: 26476535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 codon 72 polymorphism interactions with dietary and tobacco related habits and risk of stomach cancer in Mizoram, India.
    Malakar M; Devi KR; Phukan RK; Kaur T; Deka M; Puia L; Sailo L; Lalhmangaihi T; Barua D; Rajguru SK; Mahanta J; Narain K
    Asian Pac J Cancer Prev; 2014; 15(2):717-23. PubMed ID: 24568485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women.
    Noma C; Miyoshi Y; Taguchi T; Tamaki Y; Noguchi S
    Cancer Lett; 2004 Jul; 210(2):197-203. PubMed ID: 15183535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
    Yoon YJ; Chang HY; Ahn SH; Kim JK; Park YK; Kang DR; Park JY; Myoung SM; Kim DY; Chon CY; Han KH
    Carcinogenesis; 2008 Jun; 29(6):1192-6. PubMed ID: 18390844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population.
    Ezzikouri S; El Feydi AE; Afifi R; El Kihal L; Benazzouz M; Hassar M; Marchio A; Pineau P; Benjelloun S
    Cancer Detect Prev; 2009; 32(5-6):380-5. PubMed ID: 19233569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of TP53 codon 72 and MDM2 promoter 309 allelic dosage in a Moroccan population with hepatocellular carcinoma.
    Ezzikouri S; Essaid El Feydi A; Afifi R; Benazzouz M; Hassar M; Pineau P; Benjelloun S
    Int J Biol Markers; 2011; 26(4):229-33. PubMed ID: 22180176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P53 tumor suppressor gene mutations in hepatocellular carcinoma patients in India.
    Katiyar S; Dash BC; Thakur V; Guptan RC; Sarin SK; Das BC
    Cancer; 2000 Apr; 88(7):1565-73. PubMed ID: 10738214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanism of hepatocarcinogenesis.
    Sheu JC
    J Gastroenterol Hepatol; 1997 Oct; 12(9-10):S309-13. PubMed ID: 9407351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of a potential functional pre-miR-218 polymorphism and its interaction with hepatitis B virus mutations with hepatocellular carcinoma risk.
    Han Y; Pu R; Han X; Zhao J; Li W; Yin J; Zhang Y; Shen Q; Xie J; Zhang Q; Jiang S; Li J; Zhang H; Wang H; Cao G
    Liver Int; 2014 May; 34(5):728-36. PubMed ID: 24118778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.